Prognostic value of serum alpha-fetoprotein kinetics in liver failure on artificial liver support

Table 5 Statistical analysis of 3-month survival rate using a multiple logistic regression model

Variable	Three-month survival status
	OR1	95%CI	P value2	Significance
Age (per additional year)	1.03	1.01-1.05	0.005
Gender (male vs female)	0.81	0.57-1.15	0.241	NS
AFP grouping
Medium vs low	0.44	0.27-0.71	< 0.001
High vs low	0.325	0.148-0.714	< 0.001
Types of liver failure
ALF vs ACLF	0.36	0.20-0.66	0.001
SALF vs ACLF	0.46	0.26-0.81	0.007
CLF vs ACLF	0.64	0.33-1.23	0.178	NS
Liver function indicators
Blood ammonia (μmol/L)	1.01	1.00-1.01	0.002
Albumin (g/L)	0.91	0.88-0.95	< 0.001
Total bilirubin (μmol/L)	1.01	1.00-1.01	0.004
ALT (U/L)	1.01	0.98-1.03	0.467	NS
AST (U/L)	1.00	0.99-1.03	0.226	NS
γ-GT (U/L)	1.00	0.99-1.01	0.167	NS
PTA (%)	0.94	0.92-0.96	0.001

¹Odds ratio indicates the relative change in the likelihood of mortality associated with a one-unit increase (or category shift) in the independent variable.

²P < 0.05 indicates the presence of statistically significant differences, P > 0.05, not significant. Reference group: Liver failure type, acute-on-chronic liver failure; alpha-fetoprotein group, low alpha-fetoprotein group. Nagelkerke R² = 0.458; model χ² = 67.42 (P < 0.001).

OR: Odds ratio; CI: Confidence interval; AFP: Alpha-fetoprotein; ALF: Acute liver failure; ACLF: Acute-on-chronic liver failure; SALF: Subacute liver failure; CLF: Chronic liver failure; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; γ-GT: γ-glutamyl transferase; PTA: Prothrombin activity; NS: Not significant.